Automate Your Wheel Strategy on XTLB
With Tiblio's Option Bot, you can configure your own wheel strategy including XTLB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol XTLB
- Rev/Share 0.0008
- Book/Share 0.01
- PB 1.1631
- Debt/Equity 0.0254
- CurrentRatio 0.6072
- ROIC -0.3351
- MktCap 10224066.0
- FreeCF/Share 0.0
- PFCF 0.0
- PE -6.1551
- Debt/Assets 0.0161
- DivYield 0
- ROE -0.2553
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 2
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
XTL Names Mr. Noam Band as its New Chief Executive Officer
XTLB
Published: April 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: April 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”) announced today the appointment of Noam Band as the Company's new Chief Executive Officer.
Read More
About XTL Biopharmaceuticals Ltd. (XTLB)
- IPO Date 2005-09-01
- Website https://www.xtlbio.com
- Industry Biotechnology
- CEO Mr. Noam Band
- Employees 10
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.